Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MPO | P05164 | 15/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 5/20 | 0.47 |
| ▸ | TPO | P07202 | 1/20 | 0.40 |
| ▸ | DHFR | P00374 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | EPX | P11678 | 2/20 | 0.34 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.32 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.32 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.32 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.32 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22406452 | 0.89 | MPO (0.55) | MPOCYP3A4TPOPOLBEPX | |
| SCHEMBL19359534 | 0.84 | MPO (0.65) | MPOCYP3A4TPOEPXKCNH2 | |
| SCHEMBL22406622 | 0.84 | MPO (0.48) | MPOCYP3A4TPOEPX | |
| SCHEMBL22423883 | 0.84 | MPO (0.60) | MPOCYP3A4TPOEPXCYP2D6 | |
| SCHEMBL19359393 | 0.82 | MPO (0.62) | MPOCYP3A4TPOEPXSLC6A2 | |
| SCHEMBL22406426 | 0.82 | MPO (0.56) | MPOCYP3A4TPOEPXKCNH2 | |
| SCHEMBL22406387 | 0.81 | MPO (0.46) | MPOCYP3A4TPOEPX | |
| SCHEMBL22406614 | 0.81 | MPO (0.43) | MPOCYP3A4TPOEPX | |
| SCHEMBL19380957 | 0.81 | MPO (0.46) | MPOCYP3A4TPOEPX | |
| SCHEMBL22406402 | 0.81 | MPO (0.47) | MPOCYP3A4TPOEPXKCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11008317-B2 | Triazolopyridine inhibitors of myeloperoxidase and/or EPX | BRISTOL-MYERS SQUIBB COMPANY (US) | 2021-05-18 | — | — | US | disclosed |
| US-20200291016-A1 | TRIAZOLOPYRIDINE INHIBITORS OF MYELOPEROXIDASE AND/OR EPX | BRISTOL MYERS SQUIBB CO (US) | 2020-09-17 | — | — | US | disclosed |
| WO-2017161145-A1 | TRIAZOLOPYRIDINE INHIBITORS OF MYELOPEROXIDASE AND/OR EPX | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-09-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200291016-A1 | TRIAZOLOPYRIDINE INHIBITORS OF MYELOPEROXIDASE AND/OR EPX | EPX, MPO, SERPINB1 | MPO 2/4885CYP3A4 570/4885TPO 31/4885 |
| US-11008317-B2 | Triazolopyridine inhibitors of myeloperoxidase and/or EPX | EPX, MPO, SERPINB1 | MPO 2/4885CYP3A4 570/4885TPO 31/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.